Against the backdrop of rapidly expanding global demand for obesity and metabolic disease therapies, the peptide industry is entering an unprecedented structural growth cycle.

From GLP-1 single-target therapies to the fast development of multi-target agonists such as GLP-1/GIP/Glucagon, the global pharmaceutical value chain is being fundamentally reshaped.

Within this wave, Retatrutide has emerged as a key accelerator, driving upstream CDMO and raw material supply systems into a new round of large-scale capacity expansion.

Retatrutide Ignites a New Wave of Peptide Demand

As a next-generation multi-target weight-loss candidate, Retatrutide’s Phase III success continues to strengthen market expectations and significantly accelerates global demand for high-complexity peptide APIs.

Compared with traditional GLP-1-based drugs, Retatrutide introduces higher requirements in molecular structure, synthesis difficulty, and purity control, leading to:

● Significantly increased complexity in peptide synthesis processes

● Rapid growth in demand for high-purity API capacity

● Continued tightness in GMP-grade CDMO services

● Structural shortages in upstream raw materials and key intermediates

Against this background, global peptide CDMO companies are accelerating capacity expansion to meet long-term demand growth over the next 3–5 years.

If you want to understand how Retatrutide could impact global peptide API demand, please read our related article: How Could Retatrutide Reshape Global Peptide API Demand After Phase III Success?

Global Peptide CDMO Enters a “Capacity Reallocation” Phase

This expansion cycle is not simply about adding capacity, but rather a redistribution of the global supply chain.

On one hand, large CDMO companies in Europe and the United States are continuing to expand high-end biologics and peptide production capacity. On the other hand, Asian supply chains—led by China—are rapidly absorbing upstream and midstream capacity transfers, forming a more cost-efficient and responsive global network.

The industry is currently showing three clear trends:

1. High-end peptide capacity is moving toward large-scale commercialization

The transition from R&D-scale to commercial-scale production is accelerating significantly.

2. Extended CDMO order cycles

With Retatrutide and similar molecules entering late-stage clinical development, long-term capacity reservation has become the norm.

3. Upstream raw materials and API supply shifting forward

Upstream raw materials, peptide fragments, and key intermediates are increasingly being locked in earlier stages.

China Becomes a Key Pillar in the Global Peptide Supply Chain

Within the global peptide industry chain, China’s role is shifting from a cost manufacturing hub to a critical supply node.

This is particularly evident in the following areas:

● Improved large-scale production capacity for peptide APIs

● Increasing maturity of solid-phase peptide synthesis (SPPS) technologies

● Enhanced CDMO delivery efficiency and flexibility

● Stronger capability in customized intermediates and peptide fragments

With rising expectations for high-value molecules such as Retatrutide, China’s supply chain is increasingly being integrated into the core procurement systems of global pharmaceutical companies.

Opportunities Behind the Expansion Cycle: Revaluation of API and Raw Material Suppliers

In this new expansion cycle, upstream players are gaining significantly higher strategic importance, especially:

● Peptide API manufacturers

● Amino acids and protecting group raw material suppliers

● Custom peptide fragment producers

● Upstream CDMO support service providers

For downstream pharmaceutical companies, supply stability and batch consistency have become more important than cost alone. This shift is accelerating the industry transition from “price competition” to a comprehensive competition based on “quality + capacity + compliance”.

DengYueMed’s Role in the Global Peptide Supply Chain

In this rapidly evolving industry landscape, DengYueMed continues to focus on global pharmaceutical and peptide raw material supply chain services, covering multiple key areas including:

● Peptide APIs and intermediates supply

● Global API distribution

● CDMO sourcing support

● International pharmaceutical supply chain solutions

As the global peptide CDMO industry enters a capacity expansion cycle, HongKong DengYue Medicine is continuously strengthening upstream resource integration capabilities to support customers’ stable supply needs across R&D, regulatory, and commercialization stages.

We not only focus on current market demand, but also on the long-term structural changes driven by next-generation peptide molecules, aiming to provide more efficient and reliable raw material and supply chain support for global partners.

Conclusion: A New Cycle Has Begun, and Supply Chain Competition Is Just Accelerating

What Retatrutide has triggered is not just a single drug opportunity, but a systemic expansion cycle across the global peptide industry chain.

From CDMO capacity expansion, to API supply chain restructuring, and to global supply rebalancing, the industry is entering a longer-term and deeper growth phase.

In this process, partners with stable supply capabilities and global service networks will become indispensable nodes in the value chain.

DengYueMed will continue to deepen its focus on peptide raw materials and API supply, connecting global high-quality manufacturing capacity with customer demand, and providing continuous and reliable supply chain support throughout this wave of industry upgrading.